Eversept Partners, LP

13F Filings History

Latest 13F report
Q3 2024 - Nov 14, 2024
Value $
$1.3B
Signature - Title
Ron Rosenstraus - Chief Financial Officer
Location
New York, NY
Summary
This page shows a list of all the recent 13F filings made by Eversept Partners, LP. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Eversept Partners, LP reported 65 stock holdings with total value $1.3B as of Q3 2024. Top holdings included GSK, NTRA, VERA, INSM, and SNDX.
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Date Filed
Q3 2024 65 $1.3B +$145M -$326M -$181M GSK, NTRA, VERA, INSM, SNDX 13F-HR 11/14/2024, 09:08 AM
Q2 2024 72 $1.31B +$256M -$270M -$14M GSK, NTRA, INSM, TEVA, UTHR 13F-HR 8/14/2024, 09:03 AM
Q1 2024 68 $1.34B +$249M -$159M +$90M NTRA, GSK, INSP, TEVA, VERA 13F-HR 5/15/2024, 08:40 AM
Q4 2023 55 $1.02B +$200M -$184M +$16.2M NTRA, GSK, SNDX, INSP, TEVA 13F-HR 2/14/2024, 08:50 AM
Q3 2023 61 $901M +$165M -$150M +$15.1M GSK, NTRA, TEVA, UTHR, INSP 13F-HR 11/14/2023, 02:07 PM
Q2 2023 66 $947M +$185M -$324M -$139M NTRA, GSK, TEVA, UTHR, HZNP Restatement 11/8/2023, 02:50 PM
Q1 2023 58 $1.11B +$278M -$231M +$47.4M NTRA, GSK, HZNP, TEVA, UTHR Restatement 11/8/2023, 02:48 PM
Q4 2022 3 $342K $0 $0 ELDN, SNDA, BOLT New Holdings 11/8/2023, 02:46 PM
Q4 2022 62 $1.05B +$335M -$265M +$69.6M GSK, HZNP, NTRA, SNY, UTHR Restatement 11/8/2023, 02:44 PM
Q3 2022 0 $0 $0 $0 New Holdings 11/8/2023, 02:42 PM
Q3 2022 60 $843M +$230M -$364M -$134M BHVN, GSK, HZNP, NTRA, UTHR Restatement 11/8/2023, 02:40 PM
Q2 2022 0 $0 $0 $0 New Holdings 11/8/2023, 02:38 PM
Q2 2022 65 $1.02B +$344M -$266M +$78.9M BHVN, UTHR, HZNP, GSK, AZN Restatement 11/8/2023, 02:37 PM
Q1 2022 76 $1.08B +$254M -$305M -$50.5M CYH, BHVN, HZNP, GSK, UTHR Restatement 11/8/2023, 02:35 PM
Q4 2021 0 $0 $0 $0 New Holdings 11/8/2023, 02:33 PM
Q4 2021 90 $1.2B +$239M -$281M -$41.6M HZNP, CYH, UTHR, DHR, AZN Restatement 11/8/2023, 02:31 PM
Q3 2021 0 $0 $0 $0 New Holdings 11/8/2023, 02:29 PM
Q3 2021 88 $1.25B +$384M -$228M +$156M UTHR, ASND, CYH, HZNP, XLRN Restatement 11/8/2023, 02:28 PM
Q2 2021 69 $1.08B +$244M -$384M -$141M UTHR, AMRN, ARKG, HZNP, AZN Restatement 11/8/2023, 02:26 PM
Q1 2021 0 $0 $0 $0 New Holdings 11/8/2023, 02:23 PM
Q1 2021 74 $1.22B +$492M -$155M +$338M AMRN, UTHR, ARKG, ALXN, HZNP Restatement 11/8/2023, 02:21 PM
Q4 2020 0 $0 $0 $0 New Holdings 11/8/2023, 02:15 PM
Q4 2020 58 $833M +$413M -$145M +$268M AMRN, UTHR, ALXN, TGTX, AZN Restatement 11/8/2023, 02:13 PM
Q3 2020 0 $0 $0 $0 New Holdings 11/8/2023, 02:10 PM
Q3 2020 47 $444M +$109M -$284M -$175M HZNP, AMRN, TGTX, ASND, UTHR Restatement 11/8/2023, 01:56 PM
Q2 2020 63 $605M +$265M -$181M +$84.1M HZNP, TGTX, AMRN, BHVN, ASND Restatement 11/8/2023, 01:52 PM
Q1 2020 55 $380M +$163M -$180M -$17.6M ZGNX, DHR, ASND, TGTX, APLS Restatement 11/8/2023, 01:50 PM
Q4 2019 67 $492M +$180M -$68.3M +$111M GSK, ENSG, DHR, ASND, ZGNX Restatement 11/8/2023, 01:47 PM
Q3 2019 53 $319M +$99M -$97M +$2.02M GSK, ENSG, DHR, ZGNX, ASND Restatement 11/8/2023, 01:45 PM
Q2 2019 59 $350M +$77.4M -$82M -$4.54M RCM, AMRN, GSK, ZGNX, DHR Restatement 11/8/2023, 01:39 PM
Q1 2019 49 $338M +$148M -$32.2M +$116M AMRN, GSK, RCM, ZGNX, DHR Restatement 11/8/2023, 01:38 PM
Q4 2018 53 $180M +$52.4M -$36.5M +$15.9M ZGNX, GSK, RCM, AMRN, SNY Restatement 11/8/2023, 01:36 PM
Q3 2018 57 $199M +$63.9M -$76.2M -$12.3M ZGNX, RCM, AMRN, SNY, GSK Restatement 11/8/2023, 01:33 PM
Q2 2018 67 $204M +$45.3M -$52.8M -$7.51M QCP, RCM, AERI, RDUS, GSK Restatement 11/8/2023, 01:31 PM
Q1 2018 54 $198M +$83M -$46.8M +$36.1M QCP, RCM, RDUS, AERI, ABLX Restatement 11/8/2023, 01:29 PM
Q4 2017 45 $150M $0 $0 ARRY, AERI, ZGNX, VRTX, SNY Restatement 11/8/2023, 01:26 PM